Creative Biolabs, a global Contract Research Organization, has announced the launch of its integrated, one-stop antisense oligonucleotide (ASO) development services, aiming to streamline the often fragmented pipeline of ASO therapeutic development. The platform combines advanced bioinformatics, chemical synthesis, and rigorous preclinical validation to support biotechnology companies and academic institutions worldwide.
ASOs are a key modality in RNA therapeutics, but their development faces significant technical bottlenecks. Designing candidates with high binding affinity, overcoming in vivo enzymatic degradation, and achieving tissue-specific delivery remain formidable industry challenges. Traditional ASO development forces researchers to coordinate with multiple vendors for design, synthesis, and animal testing, leading to extended timelines and data inconsistency. Creative Biolabs addresses these issues by unifying the entire pipeline under one roof.
The platform offers proprietary bioinformatic optimization using thermodynamic simulation and RNA secondary structure accessibility prediction to identify optimal target regions, mitigating off-target risks. It also provides advanced chemical modification and synthesis capabilities, including versatile oligonucleotide architectures such as Gapmers and steric-blocking oligos. Synthesis scales range from milligram to multi-gram, utilizing PS backbones, PMO, and sugar modifications (2'-MOE, cEt) to improve nuclease resistance and support in vivo stability.
Precision delivery and conjugation technologies are central to the offering, solving the cellular uptake barrier through custom targeted delivery. This includes GalNAc conjugation for liver targeting, Antibody-Oligonucleotide Conjugates (AOCs) for extrahepatic tissues, and specialized LNP formulations. Robust preclinical validation provides data-rich in vitro screening, including mRNA knockdown via qPCR and cytotoxicity testing, as well as in vivo PK/PD profiling to support preclinical candidate selection.
“Many therapeutic pipelines stall because a high-affinity sequence fails under physiological conditions due to poor delivery or low stability,” stated the Chief Scientific Officer at Creative Biolabs. “Our one-stop platform eliminates these silos. By matching customized chemical modifications with precise conjugation chemistries early in the design phase, we significantly lower required doses and improve the safety profiles of our clients' candidates.”
With a robust portfolio of ready-to-use ASO products spanning oncology, genetic disorders, and neuromuscular diseases, Creative Biolabs provides the flexibility and technical expertise required to turn therapeutic concepts toward preclinical candidate development. For more information, visit https://www.creative-biolabs.com/gene-therapy/.
The launch of this one-stop platform is significant for the biotechnology and pharmaceutical industries. By addressing core hurdles such as delivery and stability early in the design phase, Creative Biolabs aims to reduce development timelines and improve the success rates of ASO candidates. This integrated approach could accelerate the availability of RNA-based treatments for oncology, genetic disorders, and neuromuscular diseases, potentially benefiting patients worldwide.
